BMC medicine
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study.
Huimin Lv, Tao Sun, Xiaoling Ling, Xinlan Liu, Jin Yang, Mengwei Zhang, Limin Niu, Shumin Chen, Zhenzhen Liu, Chengzheng Wang, Huihui Sun, Jing Wang, Huiai Zeng, Shengnan Zhao, Lanwei Guo
Published: 202610.1186/s12916-026-04643-z
Abstract
BACKGROUND: The efficacy and safety of anti-HER2 therapy and immune checkpoint inhibitors combined with chemotherapy to treat HER2-positive advanced breast cancer that has failed standard HER2-directed therapies is unknown. This study evaluated the e…
Preview only. Read the full abstract at the source